Zenith Healthcare

Zenith Healthcare EBITDA per Share

The EBITDA per Share of Zenith Healthcare (530665.BO) as of Oct 27, 2026 is -0.04 INR. In the previous year, EBITDA per Share was 0.02 INR — a change of -326.09% (lower).

EBITDA per Share

-0.04INR

YoY

-326.09%

Last updated:

EBITDA per Share of Zenith Healthcare is 2026 -0.04 INR. EBITDA per Share of Zenith Healthcare was 2025 0.02 INR. It decreases by -326.09% lower compared to the previous year.

The Zenith Healthcare EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2019
0.04 INR
Jan 1, 2020
0.10 INR
Jan 1, 2021
0.09 INR
Jan 1, 2022
0.08 INR
Jan 1, 2023
0.01 INR
Jan 1, 2024
0.05 INR
Jan 1, 2025
0.02 INR
Jan 1, 2026
-0.04 INR
The Zenith Healthcare EBITDA per Share history
YEAREBITDA per ShareYoY
-0.04INR-326.09%
0.02INR-63.23%
0.05INR+517.78%
0.01INR-91.11%
0.08INR-4.00%
0.09INR-13.06%
0.10INR+159.24%
0.04INR-62.11%
0.10INR+504.31%
0.02INR-139.19%
-0.04INR-39.38%
-0.07INR-17.04%
-0.09INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Zenith Healthcare Stock analysis

What does Zenith Healthcare do? Zenith Healthcare Ltd. manufactures pharmaceutical formulations including tablets, capsules, oral liquids, and injections for various therapeutic segments. The company sells products such as Roxythromycin Tablets, Ciprofloxacin Tablets, Azithromycine Dihydrate Suspension, Azithromycin Oral Suspension under antibiotics and anti-infective, Ranitidine Hydrochloride Tablets for gastrointestinal, Lisinopril Tablets for cardiovascular system, and Paracetamol and Aceclofenac Tablets for analgesic/anti-inflammatory categories. It also provides contract manufacturing services for all dosage forms. The company's primary customers are healthcare providers and pharmacies that purchase its branded pharmaceutical products. Zenith Healthcare targets therapeutic segments including antibiotics, gastrointestinal, cardiovascular, analgesic, and others as specified in its product portfolio. Its contract manufacturing services are offered to other pharmaceutical companies seeking production capabilities. Zenith Healthcare's revenue streams come from direct sales of its branded pharmaceutical products across multiple therapeutic segments and from contract manufacturing agreements. The company focuses on delivering products in key therapeutic areas such as antibiotics, gastrointestinal, cardiovascular, and analgesic markets where it has established product lines. Zenith Healthcare is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zenith Healthcare stock

EBITDA per Share of Zenith Healthcare is -0.04 INR in 2026.

EBITDA per Share of Zenith Healthcare changed from 0.02 INR to -0.04 INR, representing a -326.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Zenith Healthcare since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Zenith Healthcare

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Zenith Healthcare